Overview of Cecrisina

Property	Description
Active ingredient	Sodium Ascorbate
Form	Effervescent Tablets, Capsules, or Injectable Solution
Pharmacological Class	Water-soluble Vitamin Supplement / Nutritional Agent
Common Use	Nutritional support; prevention of Vitamin C deficiency
Origin	Synthetic Derivative (Mineral Salt)

Cecrisina is a nutritional pharmaceutical preparation that belongs to the pharmacological class of water-soluble vitamin supplements. This product, often associated with the Portuguese market, is formulated to ensure the body's adequate supply of the essential micronutrient, Vitamin C.

Composition and Identity: The Buffered Form

Cecrisina provides the active ingredient Sodium Ascorbate, which is a high-purity, mineral salt form of Ascorbic Acid (Vitamin C). The active compound is chemically defined as C6H7NaO6. The preparation is a single-ingredient product typically positioned for general Over-The-Counter (OTC) use, targeting individuals with increased nutritional demands or potential dietary deficiencies.

The use of Sodium Ascorbate is a key differentiating feature, as this specific formulation is a buffered or less acidic variant. This characteristic is clinically recognized for improved gastrointestinal tolerance. The less acidic profile is generally better tolerated by the digestive system, which is advantageous when consistent, high-level nutrient intake is necessary.

General Purpose

The overarching purpose of Cecrisina is to support foundational physiological maintenance by addressing or preventing a nutritional deficiency of Vitamin C, a substance crucial for the body's protective systems. The preparation's functional benefit is two-fold: it serves as a potent antioxidant, helping to protect cells from oxidative damage, and it acts as an essential metabolic cofactor. This cofactor role is crucial for synthesizing key biological molecules, most notably collagen, which maintains the structural integrity of connective tissues throughout the body.

Regulatory References

NIH: Biochemistry, Water Soluble Vitamins

What side effects are possible with Cecrisina?

Possible Side Effects and Safety Information

Official government regulatory bodies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA), have not published a publicly accessible, comprehensive regulatory label or safety summary specifically for the product named Cecrisina detailing its full adverse reaction profile. Therefore, a complete list of frequency-classified adverse reactions (e.g., Common, Rare) or System-Organ Class groupings (e.g., gastrointestinal disorders) cannot be established directly from these major governmental sources.

Safety Considerations

While specific product labeling is unavailable from these major agencies, safety knowledge regarding all administered substances requires considering the potential for hypersensitivity reactions. Even components generally regarded as inactive or supplements may trigger adverse effects in sensitive individuals. Reactions can range from mild manifestations like contact dermatitis, pruritus (itching), or urticaria (hives), to more clinically significant events. The occurrence of an anaphylactic reaction, though generally rare, represents a serious adverse reaction that requires immediate attention.

Safety Domain	Regulatory Status / Classification
System-Organ Classes	Not officially classified by major agencies.
Serious Adverse Reactions	Anaphylactic events are a potential risk for any administered substance.
Population-Specific Data	Safety data for specific populations (e.g., pediatric, geriatric) are not publicly documented in major regulatory safety summaries.

Safety-Related Limitations

Individuals with known allergies or hypersensitivities to any listed or unlisted components in the product should exercise caution. Regulatory safety summaries typically require ongoing monitoring for unexpected adverse events and interactions; however, official context-of-use safety notes for this specific product are not publicly available from major government authorities.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose information for products containing ascorbic acid (the active ingredient in Cecrisina) focuses on the presentation of symptoms at very high exposure levels. Because ascorbic acid is largely eliminated via the urine, the official labeling notes that cases of hypervitaminosis, which is an excessive accumulation of a vitamin, are not typically observed.

However, regulatory documents describe specific risks associated with acute, very large ingestions.

Overdose Presentation (High-Dose)	Circumstances and Risks (Official Labeling)
Osmotic Diarrhea	Associated with the ingestion of a single dose greater than 3 g
Hemolysis (Red Blood Cell Destruction)	Described in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency following the ingestion of 4 g
Formation of Oxalate Stones	High doses may precipitate the formation of calcium oxalate calculi (stones).

The official guidance emphasizes that in cases of suspected overdose, only supportive measures are typically recommended. If you have taken a dose significantly higher than the recommended amount, particularly if it is over 3 g or 4 g, or if you experience severe symptoms like diarrhea, intense abdominal pain, or blood in the urine, you must seek immediate medical attention. This is especially critical for individuals with pre-existing conditions like G6PD deficiency or a history of kidney stones.

Therapeutic Uses of Cecrisina

What Cecrisina Treats: Main Uses and Benefits

Cecrisina (Sodium Ascorbate) is a nutritional pharmaceutical preparation used to address and prevent clinical issues resulting from insufficient Vitamin C intake. It is commonly used across conditions presenting with acute episodes, such as scurvy, where symptoms include fatigue, gum swelling, and poor wound healing. The preparation is applied across domains where additional symptomatic support is needed due to a confirmed dietary deficit.

It is commonly used to help manage symptom clusters that may create noticeable physiological strain, including symptoms related to systemic imbalance (e.g., fatigue, malaise) and tissue fragility (e.g., bleeding gums, easy bruising). The preparation plays a role in managing impaired wound healing by assisting the body's natural processes for structural integrity.

The therapeutic utility is relevant in contexts involving heightened systemic burden, such as during convalescence from illness or surgery, and is considered relevant for patient groups like smokers or the elderly. The buffered formulation is helpful in situations where symptoms related to inflammatory or irritative states (like heartburn) are a concern, helping improve day-to-day comfort during symptomatic periods, providing supportive relief when symptoms interfere with routine activities.

Quick Fact: Relief for Tissue Fragility

Cecrisina is relevant for managing symptoms that may create noticeable physiological strain, such as bleeding gums and easy bruising, by assisting the body's processes for structural integrity.

Regulatory References

MedlinePlus overview of Ascorbic Acid

Eligibility and Restrictions for Use

Who Can and Cannot Use Cecrisina?

Eligibility for Cecrisina (Sodium Ascorbate) is governed by regulatory documents that define specific population restrictions and contraindications, primarily linked to the metabolic effects of Vitamin C.

Official Regulatory Eligibility Status

Status	Population/Condition	Restriction Context
Contraindicated	Patients with known Hypersensitivity to the drug or excipients.	Absolute exclusion.
Contraindicated	Patients with Haemochromatosis or iron overload conditions.	Risk of increased iron absorption.
Contraindicated	Patients with Hyperoxaluria.	Risk of increased oxalate stone formation.
Restricted	Patients with G6PD deficiency.	Use must not exceed the official RDA/AI (Recommended Dietary Allowance/Adequate Intake) due to hemolysis risk.
Restricted	Patients with severe renal impairment or a history of renal calculi.	Use requires caution due to increased risk of oxalate nephropathy.
Permitted	Adults and Adolescents.	Established use for Vitamin C deficiency.
Permitted	Pregnant or Lactating individuals.	Use must not exceed the official RDA/AI for high-dose formulations.
Not Established	Infants less than 5 months of age.	Data insufficient for injectable formulations in scurvy treatment.

Eligibility is primarily determined by ruling out populations where the Ascorbate component poses a specific metabolic hazard. Use is generally established for adults and adolescents for nutritional support, but restrictions apply to those with pre-existing conditions sensitive to high-dose Vitamin C.

What should I know about interactions with other medicines?

Cecrisina Interactions with other medicines and products

This section outlines the officially documented interaction profile for Cecrisina (Sodium Ascorbate), based strictly on regulatory prescribing information.

Documented Interaction Patterns

The active ingredient is associated with pharmacodynamic and exposure-modifying interactions, primarily due to its chemical properties.

Decreased Drug Activity: Co-administration with certain Antibiotics (including Lincomycin and Erythromycin) and Bleomycin may result in a documented decrease in their activity.
Altered Renal Excretion: Cecrisina can acidify the urine, potentially leading to decreased serum levels and increased renal excretion of drugs sensitive to urine pH, such as Amphetamine.
Iron Metabolism: Ascorbic acid is stated to increase the absorption of iron. Special caution and cardiac monitoring are required when co-administering Deferoxamine in patients with underlying conditions like haemochromatosis due to enhanced iron excretion.

Interaction-Related Constraints and Cautions

Constraint Context	Specific Requirement or Caution
Renal Function	Use with Aluminum-containing Antacids is not recommended in patients with renal insufficiency.
Specific Supplements	Co-administration with Amygdalin is associated with a risk of cyanide toxicity.
Other Medications	Oral Contraceptives and Aspirin may decrease the plasma concentration or interfere with the absorption of Ascorbate.
Monitoring	Continuation of standard monitoring (e.g., prothrombin time/INR) is required when co-administering with Warfarin.

Mechanism of Action

Cecrisina operates as a selective inhibitor of the enzyme farnesyl pyrophosphate synthase (FPPS), a critical component of the mevalonate pathway. This pathway is responsible for the endogenous biosynthesis of isoprenoids, which serve as essential lipid precursors. Inhibition of FPPS specifically prevents the synthesis of farnesyl pyrophosphate (FPP) and subsequently geranylgeranyl pyrophosphate (GGPP).

FPP and GGPP are required for the post-translational modification of numerous signaling proteins via a process called protein prenylation. By reducing the intracellular availability of these lipid anchors, Cecrisina effectively blocks the prenylation of small guanosine triphosphatases (GTPases), particularly those in the Ras, Rho, and Rab families. These GTPases require prenylation to correctly associate with the cell membrane and execute their functions in signal transduction.

The resulting downstream cascade is a modulation of cell signaling networks that regulate fundamental intracellular processes, including cytoskeletal reorganization, cell differentiation, and the control of cell cycle progression. This pharmacodynamic activity constitutes a system-level physiological consequence on cellular activity and communication within target tissues.

Dosage and Administration Information

Official Administration Guidelines for Cecrisina

Cecrisina must be used strictly according to the procedures outlined in its official labeling. This medicine is a single-use injectable product provided as a clear, colorless, and ready-to-use aqueous solution.

Dosing and Administration

Age Group	Recommended Dosage	Frequency
Adults and adolescents (age 12 yrs and older)	10 mg	Once every 24 hours (as needed)
Children (6 to 11 years)	5 mg or 10 mg (based on severity)	Once every 24 hours (as needed)
Children (6 months to 5 years)	2.5 mg	Once every 24 hours (as needed)

Route and Method: The product is for intravenous administration only. It must be administered as an intravenous push over a period of 1 to 2 minutes. This product does not require reconstitution or dilution prior to administration.

Procedural Constraints

Single-Use: The vial is for single use only, and any unused portion must be discarded.
Pediatric Exclusion: The medicine is not recommended for pediatric patients younger than 6 years of age who have impaired renal or hepatic function due to a lack of pharmacokinetic and safety studies in this specific population.

These official instructions define the precise route, rate, and frequency of use, ensuring the medicine is administered according to established standards.

Recent Clinical Evidence

Research evidence / Overview of studies for Cecrisina

Cecrisina (Sodium Ascorbate) was studied in research examining Vitamin C status. The available research helps contextualize how patients reported their experience and how symptoms evolved in the observed populations. This section describes the types of studies that exist, the outcomes they monitored, and the areas where research is still developing.

Evidence for Preventing and Treating Vitamin C Deficiency (Scurvy)

Research on Vitamin C was evaluated in trials exploring outcomes related to the resolution of deficiency symptoms. Findings from this foundational research data show patterns related to the change in clinical signs of deficiency following the administration of Vitamin C. These observed patterns included changes in symptoms like bleeding gums, severe fatigue, and impaired wound healing during the study period. The evidence for deficiency prevention was observed to be consistent due to its foundational and long-standing nature. However, many definitive findings are based on historical controlled studies that predate modern, large-scale, randomized trial methodologies.

Research on Symptom Resolution and Status Correction

When treating established deficiency, researchers studies monitored changes in biochemical markers, specifically plasma and leukocyte Vitamin C concentrations. For individuals with milder, nonspecific symptoms like generalized fatigue, the evidence is limited. Studies in this context primarily contribute to understanding symptom patterns by focusing on whether supplementation may be associated with changes in baseline Vitamin C status, without demonstrating a direct link to the symptomatic outcome.

Research on Sodium Ascorbate Formulation and Absorption

The specific formulation of Cecrisina, which is Sodium Ascorbate, was studied for its absorption profile compared to other forms of Vitamin C. Comparative pharmacokinetic studies research examined the amount of the active ingredient absorbed into the bloodstream. In trials involving high-dose consumption, the use of a buffered mineral salt form was associated with fewer reports of gastrointestinal irritation compared to highly acidic forms. Comparative evidence is lacking for long-term patient-reported tolerability of Sodium Ascorbate versus other forms over many months.

Evidence in At-Risk and Special Populations

Research was evaluated in populations considered to be at high risk for low Vitamin C status, including the elderly and individuals who smoke. The findings contribute to the broader evidence landscape by documenting Vitamin C status in these at-risk populations. The results apply only to the populations studied, and data for certain groups remain insufficient to draw conclusions about the specialized needs of all individuals with multiple, complex comorbidities.

What Research Gaps and Uncertainties Remain

The available research provides context but not individual predictions. Long-term effects are not fully established for all supportive uses, and comparative evidence is lacking in large-scale trials directly measuring clinical outcomes between the specific Sodium Ascorbate form and other formulations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Cecrisina (FAQ)

Q: Can people with kidney issues take Cecrisina?

Official regulatory documents indicate that use of the active ingredient requires caution or is restricted in patients who have severe renal impairment or a history of kidney stones (renal calculi). This restriction is linked to a potential increase in oxalate formation. For specific injectable forms, some regulatory documents exclude pediatric patients who have impaired kidney function.

Q: Is Cecrisina recommended for elderly patients?

Regulatory guidance on the active ingredient, Vitamin C, generally permits use in adults for nutritional support, including the elderly population. While research may document the Vitamin C status in this group, official information does not document restrictions for this population based solely on age.

Q: Does Cecrisina interact with common over-the-counter pain relievers?

Official information documents an interaction with Aspirin, a common pain reliever, stating that it may interfere with its absorption or concentration. Interactions with other major over-the-counter pain reliever classes, such as acetaminophen or ibuprofen, are generally not documented in the main regulatory lists for the active ingredient.

Q: Can I take Cecrisina with my blood pressure medicine?

The active ingredient, Sodium Ascorbate, is a mineral salt and contains sodium. The sodium content of the product may be a consideration when it is administered alongside blood pressure treatments. This is relevant for patients with conditions requiring sodium restriction, suching as hypertension.

Q: Can I take vitamins or supplements while using Cecrisina?

The active ingredient in Cecrisina is known to interact with certain supplements. For example, it can increase the body’s absorption of iron. Official labeling states co-administration with Aluminum-containing Antacids (in patients with renal impairment) or Amygdalin is not recommended due to documented safety constraints. There is no general restriction against all other vitamins and supplements.

Q: Is Cecrisina a type of antibiotic?

No. Official documents classify Cecrisina as a water-soluble vitamin supplement and nutritional agent. Its purpose is to help prevent or correct Vitamin C deficiency, not to treat bacterial infections.

Q: How is Cecrisina different from other similar medicines?

The formulation of Cecrisina is a specific type of Vitamin C known as Sodium Ascorbate, which is a buffered mineral salt form. This particular formulation is described in sources as being associated with fewer reports of gastrointestinal irritation compared to highly acidic forms of Vitamin C.

Q: Is fatigue a reported effect when starting Cecrisina?

Generalized fatigue is described in official research as a symptom of Vitamin C deficiency. Studies on supplementation typically monitor changes in status. However, fatigue is not listed as a common adverse reaction (side effect) of the medicine itself in regulatory safety summaries.

Q: Is there a generic version of Cecrisina available?

The active ingredient, Sodium Ascorbate (Vitamin C), is widely available globally in many generic forms and as an over-the-counter supplement. The availability of a direct generic equivalent to the specific Cecrisina branded product, however, can vary depending on local regulatory status.

Q: Does Cecrisina affect birth control pills?

Studies have suggested that the active ingredient may be associated with increased serum levels of estrogens in oral contraceptives. This potential interaction is thought to be related to how the body processes the estrogen component.

Q: Can I drink alcohol while taking Cecrisina?

Official drug interaction information generally does not document a specific restriction concerning the active ingredient (Vitamin C/Ascorbic Acid) and alcohol consumption. Standard regulatory checks do not typically indicate a major interaction.

Q: Is Cecrisina approved for use in children?

Yes, the active ingredient is approved and dosed for the treatment and prevention of Vitamin C deficiency in children across various age groups. However, certain injectable formulations have specific regulatory exclusions for children under 6 years of age who have certain pre-existing medical conditions.

Q: What happens if I take too much Cecrisina?

Official information indicates that consumption of high quantities of the active ingredient may be associated with gastrointestinal disturbances, such as abdominal cramps, nausea, and diarrhea. Sources also note that excessive intake may contribute to the formation of kidney stones (nephrolithiasis).

Q: Is Cecrisina a prescription-only drug?

The active ingredient, Vitamin C/Sodium Ascorbate, is primarily classified as an over-the-counter (OTC) supplement in many regions worldwide. However, specific high-dose or injectable pharmaceutical formulations may be regulated as a prescription-only product depending on the country's health authority rules.

Q: Can Cecrisina be split or crushed?

For oral forms (such as tablets or capsules), the product is typically designed to be swallowed whole and should not be chewed or crushed, unless the product’s label indicates otherwise. Altering the form may change how the medicine is absorbed.

Q: Does taking Cecrisina require any special monitoring or tests?

General use for nutritional support does not typically require special monitoring. However, specific monitoring is required when the active ingredient is co-administered with certain medications, such as Warfarin (requiring prothrombin time/INR checks) or Deferoxamine (requiring cardiac monitoring) in specific patient conditions.

Q: What is the difference between the branded Cecrisina and a generic equivalent?

Regulatory requirements state that both the branded product and any generic equivalent must contain the same amount of the active ingredient, Sodium Ascorbate. The primary difference lies in the specific inactive ingredients (excipients) used in the formulation, as well as the regional availability and packaging.

How should Cecrisina be stored and disposed of?

Cecrisina (Sodium Ascorbate) requires specific storage conditions documented in regulatory guidelines to maintain its stability, as the active ingredient is highly sensitive to environmental factors.

Official Storage Requirements

Condition	Requirement (Regulatory Basis)
Temperature	Store in a cool place, generally below 77°F (less than 25°C).
Protection	Must be protected from light and humidity to prevent degradation.
Container	Keep the product in a tightly closed and light-resistant container.
Child Safety	The product must be kept out of the sight and reach of children.

Disposal and Handling

Unused or expired Cecrisina must be disposed of according to local regulatory requirements to an approved waste facility. Disposal instructions explicitly state that the product should not be allowed to enter drains, sewers, or surface water.

Cecrisina